15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 7 firms covering Pyxis Oncology Inc, 7 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $5.00 to $8.00, a moderate spread. The average target of $6.86 sits 136% above the current $2.91. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 5 to 7 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.28 next quarter toward $-1.21 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 ratings
Moderate Buy
Strong Buy00%
Buy7100%
Hold00%
Sell00%
Strong Sell00%
Based on 7 analysts giving stock ratings to Pyxis Oncology Inc.
As of Jul, 7 of 7 firms rate PYXS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
PYXS EPS & revenue forecast
EPS · NEXT QUARTER
$-0.28
Range $-0.37 – $-0.24 · 8 analysts · -21% YoY
Next period, 8 analysts expect Pyxis Oncology Inc to earn $-0.28 a share (range $-0.37 – $-0.24), versus $-0.35 a year earlier. Full-year consensus is $-1.22, growing to $-1.21 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 8 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $50.0K, rising to $3.1M next year.
Top analysts covering Pyxis Oncology Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PYXS.
#1
Leonid Timashev
RBC Capital · Rank #69
Buy
$5.00+71.8% to target
Overall win rate
42%
+ Follow
#2
Swayampakula Ramakanth
HC Wainwright & Co. · Rank #230
Buy
$7.00+140.5% to target
Overall win rate
37%
+ Follow
#3
Robert Driscoll
Wedbush · Rank #313
Buy
$6.00+106.2% to target
Overall win rate
30%
+ Follow
#4
SL
Sudan Loganathan
Stephens & Co.
Buy
$8.00+174.9% to target
Coverage
—
+ Follow
#5
JL
Jeffrey La Rosa
Leerink Partners
Buy
$7.00+140.5% to target
Coverage
—
+ Follow
PYXS stock forecast FAQ
What is PYXS's average 12-month price target?+
The 7 analysts with a live target average $6.86 for Pyxis Oncology Inc over the next 12 months, ranging from a $8.00 high to a $5.00 low.
Is PYXS stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 7 analyst ratings, 7 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for PYXS?+
The Street-high target is $8.00 (Stifel), and the Street-low is $5.00 (RBC Capital). The average of all 7 active targets is $6.86.
How many Wall Street analysts cover PYXS?+
7 analysts have an active rating on Pyxis Oncology Inc, and 7 firms carry a live 12-month price target.
Who is the most accurate analyst covering PYXS?+
Among analysts who currently cover PYXS, Leonid Timashev of RBC Capital has the strongest overall Quantellect track record (Rank #69). Their current call is Buy with a $5.00 target.
What is Pyxis Oncology Inc's projected EPS for next quarter?+
The consensus estimate is $-0.28 per share (range $-0.37 – $-0.24) across 8 analysts. Full-year EPS is projected at $-1.22, rising to $-1.21 the following year.
How much revenue is Pyxis Oncology Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $50.0K, growing to $3.1M next year.
Have analysts been upgrading or downgrading PYXS lately?+
As of Jul, 7 of 7 firms rate PYXS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PYXS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
